Elicio Therapeutics (FRA:9HA) Volatility: 93.85% (As of Jul. 08, 2026)


FRA:9HA Elicio Therapeutics Inc FRA:9HA
10 GF Score
Price €2.80
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Volatility?

Elicio Therapeutics FRA:9HA 10 Volatility is 93.85% as of Jul. 08, 2026. GuruFocus rates FRA:9HA with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2026-07-08), Elicio Therapeutics's Volatility is 93.85%.

Elicio Therapeutics  (FRA:9HA) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Elicio Therapeutics Volatility Related Terms

FRA:9HA vs GOSS, GANX, ACET: Volatility Comparison

For the Biotechnology subindustry, Elicio Therapeutics's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elicio Therapeutics Volatility vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's Volatility distribution charts can be found below:

* The bar in red indicates where Elicio Therapeutics's Volatility falls into.


FRA:9HA
10GF Score
Elicio Therapeutics Inc FRA:9HA
Volatility is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics  (FRA:9HA) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * √12
=√ 1/(n-1) ∑(Ri - R')^2 * √12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Volatility →
What does a Volatility of 93.85% mean?
Elicio Therapeutics (FRA:9HA) has a Volatility of 93.85% as of Jul. 08, 2026. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Volatility too high?
Elicio Therapeutics' current Volatility is 93.85%. Overall, Elicio Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Volatility compare to GOSS and GANX?
Elicio Therapeutics' Volatility of 93.85% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Volatility for a Biotechnology company?
A good Volatility depends on the Biotechnology industry context. However, Volatility should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Volatility mean?
A high Volatility can signal that a stock is expensive relative to its fundamentals. Volatility is measured as the annualized standard deviation between monthly returns from the security over the past year. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Volatility is 93.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (FRA:9HA) has a current Volatility of 93.85%. The current Volatility is 93.85%. Elicio Therapeutics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Volatility calculated?
Volatility is calculated from a company's financial statements. For Elicio Therapeutics (FRA:9HA), the current Volatility is 93.85% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges ELTX:USA
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
10GF Score

Get the complete analysis for FRA:9HA

Volatility is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.80
Price